| Events | P-Y | Incidence | HR (95%CI) | P | aHR (95%CI) | P |
---|---|---|---|---|---|---|---|
CD4 cell count | |||||||
>500 | 10 | 2062 | 4.8 | ref | Â | Ref | Â |
350-499 | 20 | 1532 | 13.1 | 2.7 (1.2, 5.6) | .013 | 2.2 (1.0, 4.9) | .053 |
250-349 | 23 | 1154 | 19.9 | 4.1 (1.9, 8.6) | <.001 | 2.6 (1.2, 5.9) | .018 |
<250 | 18 | 422 | 42.7 | 8.0 (3.6, 17.7) | <.001 | 3.5 (1.4, 8.5) | .005 |
Plasma HIV-1 RNA | |||||||
<10 K | 19 | 2465 | 7.7 | ref | Â | Ref | Â |
10 K-50 K | 5 | 1340 | 3.7 | 0.5 (0.2, 1.2) | .12 | 0.5 (0.2, 1.3) | .15 |
50 K-100 K | 7 | 503 | 13.9 | 1.7 (0.7, 4.1) | .21 | 1.4 (0.6, 3.6) | .42 |
>100 K | 40 | 853 | 46.9 | 5.7 (3.2, 10.0) | <.001 | †5.8 (2.9, 11.4) | <.001 |
Antiretroviral use | |||||||
No | 60 | 4973 | 12.1 | ref | Â | ref | Â |
Yes | 11 | 197 | 55.8 | 5.6 (2.7, 11.5) | <.001 | †9.8 (4.1, 23.8) | .001 |
WHO HIV Stage | |||||||
1-2 | 36 | 4143 | 8.7 | Ref | Â | ND | Â |
3 | 24 | 988 | 24.3 | 3.1 (1.8, 5.1) | <.001 | Â | Â |
4 | 11 | 39 | 282.1 | 15.7 (6.3, 39.4) | <.001 | Â | Â |
Gender | |||||||
Men | 28 | 1708 | 16.4 | Ref | Â | Ref | Â |
Women | 43 | 3462 | 12.4 | 0.7 (0.4, 1.1) | .12 | 0.9 (0.6, 1.5) | .79 |
Age | |||||||
18-25 | 8 | 736 | 10.9 | Ref | Â | ND | Â |
26-35 | 29 | 2417 | 12.0 | 1.2 (0.5, 2.6) | .67 | Â | Â |
36+ | 34 | 2015 | 16.9 | 1.7 (0.8, 3.6) | .21 | Â | Â |
Type of housing | |||||||
Formal | 38 | 3050 | 12.5 | ref | Â | ND | Â |
Informal | 32 | 2001 | 16.0 | 1.6 (1.0, 2.7) | .071 | Â | Â |
Arm | Â | ||||||
Placebo | 38 | 2562 | 14.8 | Ref | Â | ref | Â |
Acyclovir | 33 | 2607 | 12.7 | 0.8 (0.5, 1.3) | .44 | 1.0 (0.6, 1.6) | .99 |